Company news
Travere Therapeutics, Inc. news in 2024
Travere Therapeutics, Inc.'s news releases, calls and decks from 2024, newest first.
Travere Therapeutics to Present at Upcoming Investor Conferences
November 24, 2024
Travere Therapeutics Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters’ Option to Purchase Additional Shares
November 11, 2024
Travere Therapeutics Announces Proposed Public Offering of Common Stock
November 6, 2024
Travere Therapeutics Announces Pricing of Public Offering of Common Stock
November 6, 2024
Travere Therapeutics Reports Third Quarter 2024 Financial Results
October 30, 2024
Travere Therapeutics Presents Data Reinforcing Clinical Benefit of FILSPARI® (Sparsentan) in IgAN and Late-Breaking Presentation in FSGS at ASN Kidney Week 2024
October 25, 2024
Travere Therapeutics to Report Third Quarter 2024 Financial Results
October 20, 2024
Travere Therapeutics and CSL Vifor Announce Swissmedic Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy
October 16, 2024
CSL Vifor and Travere Therapeutics Announce Swissmedic approval of FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
October 16, 2024
Travere Therapeutics to Present Abstracts at American Society of Nephrology (ASN) Kidney Week 2024
October 13, 2024
Travere Therapeutics Announces Voluntary Pause of Enrollment in the Phase 3 HARMONY Study of Pegtibatinase Related to Commercial Manufacturing Scale-Up
September 25, 2024
Travere Therapeutics to Present at the 2024 Cantor Global Healthcare Conference
September 9, 2024
Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy
September 4, 2024
Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2024
August 21, 2024
Travere Therapeutics Reports Second Quarter 2024 Financial Results
July 31, 2024
Travere Therapeutics to Report Second Quarter 2024 Financial Results
July 24, 2024
Travere Therapeutics to Present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference
July 7, 2024
Travere Therapeutics to Present at National Kidney Foundation Spring Clinical Meetings and the 61st European Renal Association Congress
May 8, 2024
Travere Therapeutics Reports First Quarter 2024 Financial Results
May 5, 2024
Travere Therapeutics to Report First Quarter 2024 Financial Results
April 28, 2024
Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
April 23, 2024
CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
April 23, 2024
Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders and Genetic Metabolic Dieticians International
April 3, 2024
Travere Therapeutics to Present Abstracts on FILSPARI® (sparsentan) in IgA Nephropathy at World Congress of Nephrology and the American Nephrology Nurses Association
April 2, 2024
Travere Therapeutics Submits Supplemental New Drug Application to the U.S. Food and Drug Administration Seeking Full Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy (IgAN)
March 10, 2024
Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA Nephropathy
February 22, 2024
CSL Vifor and Travere Therapeutics announce sparsentan receives positive CHMP opinion for the treatment of IgA nephropathy
February 22, 2024
Travere Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
February 14, 2024
Travere Therapeutics to Present at the Guggenheim 6th Annual Biotechnology Conference
January 31, 2024
Travere Therapeutics Announces Licensing Agreement with Renalys Pharma to Develop and Commercialize Sparsentan in Japan, South Korea, Taiwan, and Southeast Asian Nations
January 24, 2024
Travere Therapeutics Provides Corporate Update and 2024 Outlook
January 7, 2024
Travere Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 1, 2024
Calls in 2024
- Travere Therapeutics (NASDAQ:TVTX) Q3 2024 Earnings Call
Oct 31, 2024
Transcript - Travere Therapeutics (NASDAQ:TVTX) Q2 2024 Earnings Call
Aug 1, 2024
Transcript - Travere Therapeutics (NASDAQ:TVTX) Q1 2024 Earnings Call
May 6, 2024
Transcript - Travere Therapeutics (NASDAQ:TVTX) Q4 2023 Earnings Call
Feb 15, 2024
Transcript
Decks in 2024
- Technical Presentation (October 2024)
Technical · 17 slides · October 2024
- Technical Presentation (October 2024)
Technical · 13 slides · October 2024
- Technical Presentation (August 2024)
Technical · 6 slides · August 2024
- Technical Presentation (June 2024)
Technical · 26 slides · June 2024
- 61st European Renal Association (ERA) Congress 2024
Conference · 17 slides · May 2024
- Technical Presentation (April 2024)
Technical · 16 slides · April 2024